The comparative pharmacokinetics of modified‐release and immediate‐release paracetamol in a simulated overdose model
- 8 December 2010
- journal article
- research article
- Published by Wiley in Emergency Medicine Australasia
- Vol. 22 (6), 548-555
- https://doi.org/10.1111/j.1742-6723.2010.01354.x
Abstract
Panadol Extend (PEx) is an over-the-counter, modified-release formulation of paracetamol. Each 665 mg tablet contains 69% slow-release and 31% immediate-release paracetamol. In simulated human overdose, PEx exhibits lower and later peak serum concentrations and a lower area-under-the-curve (AUC) than comparable doses of immediate-release paracetamol (APAP-IR). The lower AUC might result from incomplete absorption of paracetamol or simultaneous metabolism with absorption. Do differences in pharmacokinetics (PK) between PEx and APAP-IR result from incomplete absorption or simultaneous absorption and metabolism of paracetamol? Cross-over study of 80 mg/kg of PEx or APAP-IR in nine volunteers. Serial plasma paracetamol, glucuronide, sulphate and cysteine metabolite estimates performed over 24 h. Peak plasma concentration (Cmax), AUC((0-∞),) time to peak concentration (Tmax) and elimination half-life (t(1/2) ) were compared. PEx exhibited significantly lower paracetamol Cmax (252.33 µmol/L vs 565.56 µmol/L, P= 0.0421), AUC((0-∞)) (2133 µmol/h/L vs 2637 µmol/h/L, P= 0.0004) and delayed Tmax (2.889 h vs 1.389 h, P= 0.0189) than APAP-IR. Sulphate metabolite PK parameters for both preparations, PEx vs APAP-IR, showed similar AUC((0-∞)) (1369 µmol/h/L vs 1089 µmol/h/L), Tmax (3.889 h vs 4.444 h), Cmax (95.889 µmol/L vs 95.889 µmol/L) and t(1/2) (3.895 h vs 3.810 h). Glucuronide metabolite concentrations revealed that PEx produced a lower Cmax (257.44 µmol/L vs 335.22 µmol/L, P= 0.0239) than APAP-IR. All other pharmacokinetic parameters were similar. Cysteine metabolite was not detected. There were minor differences between the PK parameters of the two major paracetamol metabolites of these two preparations in simulated overdose. The variability in paracetamol AUC seen between the two preparations in moderate overdose might be explained by concurrent metabolism of paracetamol during slower absorption with PEx.Keywords
This publication has 11 references indexed in Scilit:
- Overdose with modified‐release paracetamol results in delayed and prolonged absorption of paracetamolInternal Medicine Journal, 2010
- Prolonged absorption and delayed peak paracetamol concentration following poisoning with extended‐release formulationThe Medical Journal of Australia, 2008
- Disposition of Acetaminophen at 4, 6, and 8 g/day for 3 Days in Healthy Young AdultsClinical Pharmacology & Therapeutics, 2007
- Comparative pharmacokinetics of Panadol Extend and immediate‐release paracetamol in a simulated overdose modelEmergency Medicine Australasia, 2006
- Pharmacokinetic Effects of Diphenhydramine or Oxycodone in Simulated Acetaminophen OverdoseAcademic Emergency Medicine, 2005
- Analgesic efficacy of sustained release paracetamol in patients with osteoarthritis of the kneeBritish Journal of Clinical Pharmacology, 2002
- Efficacy of Oral N-Acetylcysteine in the Treatment of Acetaminophen OverdoseThe New England Journal of Medicine, 1988
- Drug conjugation in clinical toxicologyBiochemical Society Transactions, 1984
- Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning.BMJ, 1979
- Acetaminophen Poisoning and ToxicityPEDIATRICS, 1975